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The Editorial on the Research Topic
Alternative Therapeutics against MDR Bacteria – “Fighting the Epidemic of Antibiotic
Resistance”
The introduction of the first antibiotic, followed by the “golden age” of antibiotic discovery was
expected to herald the end of infectious diseases. However, microbial evolution in response to
antibiotic selection pressure has ended that expectation. The rise of resistance coincided with
a decline in the discovery of new antibiotics. With some infections now essentially untreatable,
initiatives are being put in place to redress this situation.
Among the Enterobacter species, resistance in Enterobacter aerogenes and E. cloacae is rising.
Davin-Regli and Pagès provide an overview of the factors that contribute to this and to the
dissemination of Enterobacter spp.. These authors discuss how the prevalence of multiresistant
isolates of Escherichia coli and Klebsiella pneumoniae frommajor international clones has increased
during the last decade while the incidence of E. aerogenes, which has proven unable to develop a
major clone to date, has declined significantly. This is supported by recent findings that diverse
fitness associated with resistance to fluoroquinolones influenced the selection of these major clones
(Fuzi, 2016). Additionally, these clones retain fitness by developing high-level fluoroquinolone
resistance without using energy-consuming eﬄux (Tóth et al., 2014; Johnson et al., 2015). The fact
that active eﬄux systems are widespread in E. aerogenes supports this concept (Chevalier et al.,
2008).
In the battle against these and other pathogens, rapid detection and characterization of
their drug resistance profile is crucial. Nanotechnology-based approaches have allowed for the
development of fast and sensitive detection methods for various pathogens. In their review,
Baptista and co-workers discuss the use of gold nanoparticles to screen molecular signatures of
drug resistance (Veigas et al.). These authors provide a critical evaluation of current and future
developments of technologies assisting pathogen identification and characterization of antibiotic
resistance profiles.
The use of antimicrobial peptides has been investigated due to their broad-spectrum activity.
Roy and co-workers reported the use of a modified broth of Bacillus subtilis showing activity against
multidrug-resistant Staphylococcus aureus, S. epidermidis, Streptococcus pyogenes and Enterococcus
faecalis (Chalasani et al.). This and other lead molecules are needed to treat different types of
infections caused by pathogens, like S. aureus. In prosthetic vascular grafts S. aureus leads to high
morbidity and mortality. Due to its role in virulence and biofilm formation, the Staphylococcal
accessory regulator A (SarA) constitutes an attractive target for anti-biofilm agent development.
Princy and co-workers performed a structure-based screening of lead compounds to identify
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novel small inhibitors targeting SarA (Arya et al.). A top-hit
selective inhibitor was reported to prevent attachment of S.
aureus to an epithelial cell line and inhibit the colonization of
multidrug-resistant S. aureus in an animal model. In addition,
they performed an in silico design of a hybrid molecule composed
of a molecule screened fromM. dubia and a modified SarA-based
inhibitor (Balamurugan et al.). They aimed to develop a molecule
targeting SarA. Based on their results, the hybrid molecule alone
and in combination with gentamicin was able to reduce the
biofilm structure and kill the bacteria. This can be a promising
candidate molecule to be used alone or, in combination with an
antibiotic to treat urinary tract infections caused by S. aureus.
Combination therapy has been explored for the treatment of
infections caused byMycobacterium tuberculosis.M. tuberculosis
intrinsic resistance to antimicrobials has been attributed mainly
to reduced permeability of the cell wall. Allied to this, eﬄux
systems extrude drugs from the bacteria. As these systems play
a crucial role in mediating multidrug-resistance, inhibiting eﬄux
is an attractive approach. Viveiros and co-workers performed
an elegant study in clinical isolates of multidrug-resistant M.
tuberculosis using single combinations of antituberculosis drugs
and eﬄux inhibitors (Coelho et al.). In this study, synergies
between isoniazid, rifampicin, amikacin and ofloxacin, and the
inhibitors verapamil, thioridazine and chlorpromazine were
reported. Taken together, their results confirm that in multidrug-
resistantM. tuberculosis the intrinsic eﬄux activity contributes to
the overall resistance and the inhibition of eﬄux can enhance the
effect of antibiotics.
The empty drug discovery pipeline has lead to a re-focus of
research into finding new uses for existing drugs. Anticancer,
antifungal, anthelmintic and anti-inflammatory drugs with
antimicrobial properties have been discovered. García-
Contreras and co-workers discuss alternative approaches to
treat bacterial infections by repurposing existing drugs as
antibiotics or virulence inhibitors (Rangel-Vega et al.). The use
of anticancer gallium compounds or drugs such as niclosamide
are some examples. Other drugs such as 5-fluorouracil,
azithromycin, ceftazidime and ciprofloxacin, are known to
decrease the expression of quorum sensing controlled virulence
factors.
In this battle against resistance the use of bioengineered
bacteriophage lysins is being explored. These highly specific
hydrolases present broader killing spectrum. When engineered,
they can be used as recombinant enzymes against Gram-
positive bacteria, causing rapid lysis upon direct contact
with peptidoglycan. This ability has laid the foundation for
exploiting them as powerful antimicrobials. Additionally, they
can selectively target specific pathogens without affecting
surrounding microbiota. In their mini-review, Wei and co-
workers summarize the current knowledge on lysins and their
possible uses as antimicrobials (Yang et al.). They review their
modular structure, mode of action and modifications to improve
their lytic activity.
Siderophores are ferric ion specific chelating agents, secreted
by bacteria and fungi under low iron conditions. Their main
role is to scavenge the essential mineral from the surrounding
environment, making it available to the microbial cell. Due
to their essential role in virulence and microbial survival,
siderophores have become subject of interest for use as target
delivery of antimicrobials. In their general commentary, de
Carvalho and Fernandes discuss the “Trojan Horse” approach,
i.e., the use of siderophores to tackle multidrug-resistance. They
present an overview of approaches that take advantage of the
iron transport system and of the work being conducted to
improve antibiotic uptake by pathogenic bacteria, by designing
siderophore-antibiotic conjugates.
In summary, this research topic focused on new
methodologies to identify antimicrobial resistance genes,
discovery of new molecules and repurposing of old ones. In
addition, novel therapies combining “old” antibiotics and eﬄux
inhibitors could be an avenue to explore in the future treatment
of multidrug-resistant infections.
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